RecruitingPhase 2NCT05414409
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
The Gut Microbiome in Lean and Overweight Youth With Type 1 Diabetes and Novel Mechanism of Action of Metformin
Sponsor
Heba M. Ismail
Enrollment
114 participants
Start Date
Sep 30, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Eligibility
Min Age: 11 YearsMax Age: 18 Years
Inclusion Criteria2
- Overweight/obese youth 11-18 years of age with T1D at time of enrollment.
- Lean youth 11-18 years of age with T1D at time of enrollment.
Exclusion Criteria6
- Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).
- History of ongoing infection or antibiotic treatment within the past month;
- History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months.
- History of chronic gastrointestinal disease and active within the past 6 months, possible or confirmed celiac disease.
- Participation in any research intervention trials within the past 3 months.
- History of treatment or use of metformin, a type 2 diabetes medication.
Interventions
DRUGMetformin
Metformin is an oral medication that improves insulin sensitivity.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05414409
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
NCT070107571 location
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location